

**AMENDMENTS TO THE CLAIMS/LISTING OF CLAIMS**

No claim is amended. This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously presented) A method of treating obesity in a human subject consisting of administering to said subject an amount effective to inhibit weight gain or induce weight loss in said human subject of a composition comprising an amylin or an amylin agonist and a pharmaceutically acceptable carrier, wherein said subject is in need of treatment for obesity.

2. (Previously presented) The method according to claim 1 wherein said amylin agonist is an amylin agonist analogue.

3. (Previously presented) The method according to claim 2 wherein said amylin agonist analogue is <sup>25,28,29</sup>Pro-h-amylin (SEQ ID NO:1).

4. (Previously presented) The method according to claim 1 wherein said composition is administered subcutaneously.

5. (Previously presented) The method according to claim 4 wherein said composition is administered from 1 to 4 times per day.

6. (Previously presented) The method according to claim 5 wherein said amylin or amylin agonist contained in said composition is administered in an amount from 30 µg/dose to 300 µg/dose.

7. (Previously presented) A method of treating obesity in a human subject comprising administering to said subject an amount effective to inhibit weight gain or induce weight loss of a composition comprising an obesity relief agent consisting of an amylin or an amylin agonist and a pharmaceutically acceptable carrier, wherein said amount is effective to treat obesity in said subject, and wherein said subject is in need of treatment for obesity.

8. Canceled.

9. (Previously presented) The method according to claim 1, 2 or 3 wherein the

composition is administered QID and contains said amylin or amylin agonist in an amount of 30  $\mu\text{g}/\text{dose}$ .

10. (Previously presented) The method according to claim 1, 2 or 3 wherein the composition is administered TID or QID and contains said amylin or amylin agonist in an amount of 60  $\mu\text{g}/\text{dose}$ .

11. (Previously presented) The method according to claim 1, wherein said amylin or amylin agonist contained in said composition is administered in an amount of about 0.01 milligrams per day to about 5 milligrams per day.

12. (Previously presented) The method according to claim 1, wherein said amylin or amylin agonist contained in said composition is administered in an amount of about 0.05 milligrams per day to about 2 milligrams per day.

13. (Previously presented) The method according to claim 1, wherein said amylin or amylin agonist contained in said composition is administered in an amount of about 0.1 milligrams per day to about 1 milligram per day.

14. (Previously presented) A method of treating obesity in a human subject comprising administering to said subject a compound selected from the group consisting of an amylin, an amylin agonist, and salts thereof, wherein said compound is administered in an amount effective to treat obesity in said subject by inhibiting weight gain or inducing weight loss, wherein said subject is in need of treatment for obesity, and wherein said compound is not administered in conjunction with another obesity relief agent.

15. (Previously presented) The method of claim 1, 2 or 3, wherein the weight of said human subject is reduced after four weeks of said treatment from the weight of said subject prior to said treatment.

16. (Previously presented) A method of treating obesity in a human subject comprising administering to said subject an amount effective to inhibit weight gain or induce weight loss in said subject of a composition consisting essentially of an amylin or an amylin agonist, wherein said amount is effective to treat obesity by inhibiting weight gain or inducing weight loss in said subject, and wherein said subject is in need of treatment for obesity.

17. (Previously presented) The method of claim 7, 14 or 16, wherein said amylin agonist is <sup>25,28,29</sup>Pro-h-amylin (SEQ ID NO:1).